A Phase I/II Clinical Trial of Intradermal, Controllable Self-Replicating Ribonucleic Acid Vaccine EXG-5003 against SARS-CoV-2.
Koseki T, Teramachi M, Koga M, Ko MSH, Amano T, Yu H, Amano M, Leyder E, Badiola M, Ray P, Kim J, Ko AC, Achour A, Weng NP, Imai T, Yoshida H, Taniuchi S, Shintani A, Fujigaki H, Kondo M, Doi Y.
Koseki T, et al. Among authors: ko ac.
Vaccines (Basel). 2023 Nov 27;11(12):1767. doi: 10.3390/vaccines11121767.
Vaccines (Basel). 2023.
PMID: 38140172
Free PMC article.